146 related articles for article (PubMed ID: 37019729)
1. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
[TBL] [Abstract][Full Text] [Related]
2. Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
Chartier-Kastler E; Normand LL; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Melotti A; Abouihia A; Keller DUJ; Cornu JN
Eur Urol Focus; 2022 Sep; 8(5):1399-1407. PubMed ID: 34334342
[TBL] [Abstract][Full Text] [Related]
3. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
[TBL] [Abstract][Full Text] [Related]
5. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
6. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
7. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Thiery E
Urology; 2016 Aug; 94():57-63. PubMed ID: 27131966
[TBL] [Abstract][Full Text] [Related]
8. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
9. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
Noblett K; Berg KC; Kan F; Siegel S
Neurourol Urodyn; 2018 Jun; 37(5):1667-1671. PubMed ID: 29635879
[TBL] [Abstract][Full Text] [Related]
10. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
12. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
[TBL] [Abstract][Full Text] [Related]
13. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
14. Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(3):1-64. PubMed ID: 23074472
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
16. Prospective, multicenter study to evaluate performance and safety of a re-engineered temporary lead for InterStim™ therapy evaluation.
Elterman D; Michaels J; Margolis E; Harris-Hicks J; Burgess K; Betts C; Harding C; Towers G; Hashim H; Ojo-Carons A; White A; Cannon-Smith T; Grunow N; Bittner K; Xavier K
Neurourol Urodyn; 2022 Nov; 41(8):1731-1738. PubMed ID: 35900298
[TBL] [Abstract][Full Text] [Related]
17. Sacral Neuromodulation Using a Novel Device with a Six-contact-point Electrode for the Treatment of Patients with Refractory Overactive Bladder: A Multicenter, Randomized, Single-blind, Parallel-control Clinical Trial.
Liao L; Zhou Z; Chen G; Xu Z; Huang B; Chong T; Chen Q; Wei Z; Shen B; Chen Z; Ling Q; Weng Z; Jiang H; Shi B; Li Y; Wang Y
Eur Urol Focus; 2022 Nov; 8(6):1823-1830. PubMed ID: 35525837
[TBL] [Abstract][Full Text] [Related]
18. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
[TBL] [Abstract][Full Text] [Related]
19. Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems.
Meng L; Tian Z; Zhang Y; Wang J; Liao L; Chen G; Tian X; Ma L; Li Y; Shi B; Zhang Y; Ling Q; Zhang P; Wei Z; Zhong T; Xu Z; Li J; Luo D
Sci Rep; 2022 Dec; 12(1):22299. PubMed ID: 36566332
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
